Harvard College

Olga Kandror

Alfred L Goldberg

Eric J Rubin

Tatos Akopian

Ravikiran M Raju

Meera Unnikrishnan

The technology described herein relates to treatments for tuberculosis which target the ClpP1P2 protease complex, including ClpC1. Further embodiments relate to assays and screens for modulators of the ClpP1P2 protease complex, including ClpC1.

[object Object]

Methods are disclosed which employ cold-shock proteins, such as Trigger Factor, to confer cold-tolerance to cells and to enhance viability of cells at temperatures at which the cells would not normally remain viable. Proteins having peptidyl-proline isomerase activity are also disclosed as being useful to confer cold-tolerance to cells. Cells which overexpress cold-shock proteins are useful in cell-based expression systems which are intended to express proteins at low temperatures.

Growing community of inventors

Newton, MA, United States of America

Olga Kandror